Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease in more than a decade.

Researchers from Tel Aviv University and the Israel Institute for Biological Research in Ness Ziona have used the platform ...

Merck said Wednesday it would pay $10 billion to buy the biotech Verona Pharma, which sells a new lung-disease drug that ...

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond ...

However, yesterday’s shock twist out of Washington could test just how tough Big Pharma really is, with health care stocks ...

Ireland has long been a global pharmaceutical powerhouse, hosting more than 90 pharmaceutical companies and employing around ...

Merck & Co. said Wednesday it will acquire London-based Verona Pharma in a $10 billion all-cash deal, bolstering its respiratory treatment portfolio as the company moves to reduce long-term dependence ...